119 related articles for article (PubMed ID: 37243903)
1. Ligand-Directed H
Cai X; Zhang J; Ye H; Cui K; Hao T; Yi L; Yang X
Chemistry; 2023 Aug; 29(44):e202301105. PubMed ID: 37243903
[TBL] [Abstract][Full Text] [Related]
2. PSMA-targeted NIR probes for image-guided detection of prostate cancer.
Cilibrizzi A; Wang JT; Memdouh S; Iacovone A; McElroy K; Jaffar N; Young JD; Hider RC; Blower P; Al-Jamal K; Abbate V
Colloids Surf B Biointerfaces; 2022 Oct; 218():112734. PubMed ID: 35952398
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Optimized Anti-Prostate-Specific Membrane Antigen Single-Chain Variable Fragment-Loaded Nanobubbles as a Novel Targeted Ultrasound Contrast Agent for the Diagnosis of Prostate Cancer.
Ding Y; Cao Q; Qian S; Chen X; Xu Y; Chen J; Shen H
J Ultrasound Med; 2020 Apr; 39(4):761-773. PubMed ID: 31702068
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Evaluation of
Banerjee SR; Minn I; Kumar V; Josefsson A; Lisok A; Brummet M; Chen J; Kiess AP; Baidoo K; Brayton C; Mease RC; Brechbiel M; Sgouros G; Hobbs RF; Pomper MG
J Nucl Med; 2020 Jan; 61(1):80-88. PubMed ID: 31253744
[TBL] [Abstract][Full Text] [Related]
6. Development of a complementary PET/MR dual-modal imaging probe for targeting prostate-specific membrane antigen (PSMA).
Moon SH; Yang BY; Kim YJ; Hong MK; Lee YS; Lee DS; Chung JK; Jeong JM
Nanomedicine; 2016 May; 12(4):871-879. PubMed ID: 26739097
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Evaluation and Pilot Clinical Study of Al
Liu T; Liu C; Xu X; Liu F; Guo X; Li N; Wang X; Yang J; Yang X; Zhu H; Yang Z
J Nucl Med; 2019 Sep; 60(9):1284-1292. PubMed ID: 30796170
[TBL] [Abstract][Full Text] [Related]
8. In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe.
Mazzocco C; Fracasso G; Germain-Genevois C; Dugot-Senant N; Figini M; Colombatti M; Grenier N; Couillaud F
Sci Rep; 2016 Mar; 6():23314. PubMed ID: 26996325
[TBL] [Abstract][Full Text] [Related]
9. Targeted fluorescent imaging of a novel FITC-labeled PSMA ligand in prostate cancer.
Zhou H; Gao Y; Liu Y; Wu Y; Fang Y; Wang B; Xu B
Amino Acids; 2022 Jan; 54(1):147-155. PubMed ID: 34800176
[TBL] [Abstract][Full Text] [Related]
10. A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer.
Dam JH; Olsen BB; Baun C; Høilund-Carlsen PF; Thisgaard H
Mol Imaging Biol; 2017 Dec; 19(6):915-922. PubMed ID: 28924629
[TBL] [Abstract][Full Text] [Related]
11. Photosensitizer-based multimodal PSMA-targeting ligands for intraoperative detection of prostate cancer.
Derks YHW; Rijpkema M; Amatdjais-Groenen HIV; Kip A; Franssen GM; Sedelaar JPM; Somford DM; Simons M; Laverman P; Gotthardt M; Löwik DWPM; Lütje S; Heskamp S
Theranostics; 2021; 11(4):1527-1541. PubMed ID: 33408764
[TBL] [Abstract][Full Text] [Related]
12. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific membrane antigen targeted protein contrast agents for molecular imaging of prostate cancer by MRI.
Pu F; Salarian M; Xue S; Qiao J; Feng J; Tan S; Patel A; Li X; Mamouni K; Hekmatyar K; Zou J; Wu D; Yang JJ
Nanoscale; 2016 Jul; 8(25):12668-82. PubMed ID: 26961235
[TBL] [Abstract][Full Text] [Related]
14. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Evaluation of
Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of a novel BODIPY-labeled PSMA inhibitor.
Son SH; Kwon H; Ahn HH; Nam H; Kim K; Nam S; Choi D; Ha H; Minn I; Byun Y
Bioorg Med Chem Lett; 2020 Feb; 30(3):126894. PubMed ID: 31874825
[TBL] [Abstract][Full Text] [Related]
17.
Lee BS; Chu SY; Jung WJ; Jeong HJ; Lee K; Kim MH; Kim MH; Chi DY; Ahn H; Lee YJ; Lee KC; Lim SM
Prostate; 2020 Dec; 80(16):1383-1393. PubMed ID: 32960990
[TBL] [Abstract][Full Text] [Related]
18. Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen.
Wang X; Tsui B; Ramamurthy G; Zhang P; Meyers J; Kenney ME; Kiechle J; Ponsky L; Basilion JP
Mol Cancer Ther; 2016 Aug; 15(8):1834-44. PubMed ID: 27297866
[TBL] [Abstract][Full Text] [Related]
19. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer.
Lapi SE; Wahnishe H; Pham D; Wu LY; Nedrow-Byers JR; Liu T; Vejdani K; VanBrocklin HF; Berkman CE; Jones EF
J Nucl Med; 2009 Dec; 50(12):2042-8. PubMed ID: 19910433
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.
Schottelius M; Wurzer A; Wissmiller K; Beck R; Koch M; Gorpas D; Notni J; Buckle T; van Oosterom MN; Steiger K; Ntziachristos V; Schwaiger M; van Leeuwen FWB; Wester HJ
J Nucl Med; 2019 Jan; 60(1):71-78. PubMed ID: 30237214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
